FDA rejects Pozen's aspirin drug for second time; shares plunge 20%
December 17, 2014 at 09:33 AM EST
Chapel Hill drug developer Pozen saw its shares drop nearly 20 percent in pre-market trading after it disclosed the FDA did not approve its latest drug application...